No Data
Assessing Ionis Pharmaceuticals: Insights From 8 Financial Analysts
Redburn Atlantic Initiates Ionis Pharmaceuticals at Neutral With $39 Price Target
Ionis to Present at Upcoming Investor Conferences
UBS Initiates Ionis Pharmaceuticals(IONS.US) With Hold Rating, Announces Target Price $45
Express News | Ionis Expands Partnership With Sobi to Include Olezarsen Commercialization Outside the U.S.
Express News | Ionis Pharmaceuticals Announced That It Has Entered Into A License Agreement Under Which Sobi Receives Exclusive Rights In Countries Outside The U.S., Canada And China To Commercialize Olezarsen As A Potential Treatment For Familial Chylomicronemia...
